Helena Cowley, MBA, MS

Helena Cowley is the President and CEO of Oxidien Pharmaceuticals. She has over 10 years of experience in pharma, medical device, and food, mainly in entrepreneurial start-up environments. Prior to Oxidien, Helena was part of the executive management team at Captozyme, Inc., a contract development and manufacturing organization she built alongside the two scientific co-founders, which was acquired in 2019 by Arranta Bio. Over Helena’s tenure Captozyme tripled revenues and was named among the top 50 fastest-growing University of Florida alumni-led businesses on the annual 2019 Gator100 and named a “Florida Company to Watch” by GrowFL in 2017.

Helena is a co-inventor on two patents and received the Governor’s Entrepreneur Award in 2015 for creating jobs through an innovative business. Ms. Cowley holds a Master’s in Business Administration, M.B.A., from the University of Florida, and a Master of Science in Bioengineering, from Chalmers Technical University, Gothenburg, Sweden.